Towa Pharmaceutical Co., Ltd. (FRA:6QC)

Market Cap	1.01B +22.4%
Revenue (ttm)	1.51B +6.8%
Net Income	44.52M -48.3%
EPS	0.90 -48.3%
Shares Out	n/a
PE Ratio	22.79
Forward PE	n/a
Dividend	0.43 (2.17%)
Ex-Dividend Date	Sep 29, 2026

Volume	n/a
Open	20.00
Previous Close	20.60
Day's Range	20.00 - 20.00
52-Week Range	15.20 - 23.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2026

About Towa Pharmaceutical

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. The company operates through two segments; Domestic and Overseas. It provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from tablets, capsules, injectable, patches, eye drops, and other products. The company also offers IT service related to healthcare; disease risk testing services; and sale of...

• Industry: Pharmaceutical Preparations
• Founded: 1951
• Employees: 4,923
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6QC

Financial Performance

In fiscal year 2026, Towa Pharmaceutical's revenue was 273.71 billion, an increase of 5.44% compared to the previous year's 259.59 billion. Earnings were 5.25 billion, a decrease of -72.35%.

Financial numbers in JPY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 20, 2026

Data Sources Report a data error